National Cancer Institute

Slides:

Advertisements

Similar presentations

1 CPCRN Mission To accelerate the adoption of evidence- based cancer prevention and control in communities.

Advertisements

Minorities and the medically underserved in clinical trials Edward L. Trimble, MD, MPH CTEP, DCTD, NCI.

1 NCORP Overview November 2013 NCORP Director Worta McCaskill-Stevens, MD, MS Chief, Community Oncology and Prevention Trials Research Group Division of.

PLENARY SESSION Fall Group Meeting Miami, FL November 13, 2010.

Kathryn E. Weaver, PhD, MPH co-Principal Investigator, WF NCORP RB Presentation to Translational Cancer Genomics Working Group December 16 th, 2014.

Living with and beyond treatment for cancer – the challenge for secondary care Nigel Acheson Medical Director Peninsula Cancer Network.

Institute for Health and Society Institute for Health and Society Improving Health and Advancing Health Equity Through Community and Academic Partnerships.

 Lowell Smith Sr. Director, Business & Communication Research Administration Moffitt Cancer Center  Jeanine Stiles Chief Administrative Officer Associate.

Cancer Program Standards 2012: Ensuring Patient-Centered Care

ONE Medical Center Update Steven G. Gabbe, MD Senior Vice President and Chief Executive Officer OSU Medical Center September 12, 2009.

CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.

Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.

Assessing Minority Participation in Clinical Trials: Setting Attainable Goals The Minority and Women Clinical Trials Recruitment Program Department of.

Caveats We are interpreting the guidelines along with you We may have some limited additional insight due to participation during the course of planning.

System Director, Oncology Service Line

NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.

1 Targeted Strategies to Improve Physician and Patient Access to Cancer Clinical Research An Overview of Coalition Programs and Services Ruth Lambersky.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Connecting South Carolina: The Gibbs/Hollings Cancer Center An NCCCP/NCI Designated Center Connection Anita L. Harrison, MPH Associate Director, Administration.

National Program of Cancer Registries

The Role of Physician-Patient Communication in Cancer Clinical Trials Terrance Albrecht, Ph.D. Professor Department of Interdisciplinary Oncology University.

Sanford USD Medical Center Sioux Falls, SD Becky Nelson, Senior VP & COO Health Service Operations Sanford Health.

Survivorship Research Breast Oncology Program Breast Cancer: From Basics to Beyond Lab Med UCSF Helen Diller Family Comprehensive Cancer Center.

Jim Macrae Associate Administrator U.S. Department of Health and Human Services Health Resources and Services Administration Bureau of Primary Health Care.

Gynecologic Oncology Group Gynecologic Oncology Group (GOG) Sharon Stockman, C-CRC The University of Iowa Hospitals Iowa City, IA Chair, GOG Data Management.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

Slide 1 Community Networks to Reduce Cancer Health Disparities Pre-Application Conference May 26, 2004 Bethesda, MD Kenneth C. Chu, PhD Chief, Disparities.

The KU Wichita Center for Breast Cancer Survivorship Judy Johnston, MS, RD/LD Research Instructor Department of Preventive Medicine and Public Health,

Avera Marshall Bi-Annual Update August Topics Avera Cancer Institute Marshall Avera Medical Group Marshall Expanded Footprint Avera Morningside.

James D. Bearden, III, MD, FACP Principle Investigator Gibbs Cancer Center, Spartanburg, SC Gibbs Cancer Center Our NCCCP Journey 1.

Joni Reynolds, RN-CNS, MSN Director of Public Health Programs Winnable Battles: Cancer in Colorado.

Maryland’s Cigarette Restitution Program Georges C. Benjamin, MD FACP, Secretary Maryland Department of Health and Mental Hygiene November 2000 Protecting.

The HMO Research Network (HMORN) is a consortium of research centers working in close partnership with health systems. Members conduct public domain health.

Preventing 3 Million Premature Deaths Helping 5 Million Smokers Quit A National Action Plan for Tobacco Cessation Michael C. Fiore, M.D., M.P.H., Chair.

PAIN CONTROL AMONG CANCER SURVIVORS IN OHIO 2010 Robert W. Indian, Chief Mary Lynn, Researcher Debbie Wallace, Administrative Assistant Comprehensive Cancer.

Penn Medicine Arthur H. Rubenstein, MBBCh October 26, ITMAT Symposium.

Evaluation Plan Steven Clauser, PhD Chief, Outcomes Research Branch Applied Research Program Division of Cancer Control and Population Sciences NCCCP Launch.

NCI Community Cancer Centers Program (NCCCP) Kate Castro, RN, MS, AOCN ® Nurse Consultant National Cancer Institute, Outcomes Research Branch Kate Castro,

ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.

NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.

© UEG Presentation by Towards more coordination in health research: a report on the UEG research symposium 16/11/2012 Michael Manns General Assembly.

Overview: Evidence-based Health Promotion and Disease Management Programs.

Learning Health Systems: Working at the Intersection of Research, Operations and Big Data Welcome May 5, 2017.

NCI: Programmatic Overview of CIPN Portfolio March, 2017

Opioid Management in Primary Care Michael Parchman, MD, MPH

NATIONAL outreach Network

MacColl Center for Health Care Innovation

Establishment of SWOG Publications Committee

Oncology Clinical Trials

Accelerating Precision Medicine for Advanced Cancer Patients

National and International Efforts worth knowing about

Challenges of Cancer in Vermont and Rural Northern New England

Comparing automated mental health screening to manual processes in a health care system Josh biber.

Pharmacists Optimizing Cancer Care

Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective.

PCORI Research Priorities and Relevant Examples

NRG Main Members Lead Academic Performance Sites (LAPS) 30

Report of the Clinical Protocol Committee: Development of Randomized Trials for Malignant Bowel Obstruction Thomas Anthony, MD, Todd Baron, MD, Sebastiano.

NRG Oncology Biospecimen Bank Report NRG Semiannual meeting

Sustaining Primary Care-Public Health Partnerships for Engagement in Care – The Partnerships for Care Demonstration Project Sue Lin, PhD, MS Director,

Clinical Trial Development: NRG Processes and NCI Requirements

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Association Between Symptom Distress and Survival in Outpatients Seen in a Palliative Care Cancer Center J. Lynn Palmer, PhD, Michael J. Fisch, MD, MPH

Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer:

Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development.

Lung Cancer Clinical Advisory Group

NAACCR/IACR Annual Conference, June 2019

Clinical Trial Development: NRG Processes and NCI Requirements

Cancer Symptom Trials (CST)

Center for Clinical and Translational Science

Presentation transcript:

National Cancer Institute NCI Community Oncology Research Program (NCORP) & SWOG “Leading Cancer Research. Together” National Cancer Institute Heng Xie, M.D., M.P.H., Ph.D. Community Oncology and Prevention Trials Research Group Division of Cancer Prevention SWOG NCORP Research Base Clinical Trials Workskhop September 14, 2016 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health

Outline NCORP and SWOG at a Glance NCORP's Research Agenda How Does SWOG Contribute to NCORP’s Goals? SWOG’s Achievements

NCORP at Glance: FY 2015 Funding 7 Research Bases Total FY 2015 awards - $41.8M 34 Community Sites 12 Minority/Underserved Community Sites Total FY 2015 awards $9.4M

SWOG at a Glance >12,466 cancer researchers at more than 1032 institutions 24 NCI-designated Cancer Centers 6 other countries 30 NCORP affiliates (677 embedded components and 4 NCORPs are NCI designated Cancer Centers) >200,000 patients enrolled onto more than 1,000 trials since 1956 At least 12 major cancer drug approvals in cancer treatment Establishment of the Veterans Administration Integration Support Program National innovative precision medicine trials (Lung-MAP and Moonshot Program)

Cancer care deliver research Cancer disparities NCORP's Research Areas Clinical trials Cancer care deliver research Cancer disparities

NCORP's Overall Research Agenda Reducing cancer risk and incidence Improving cancer care outcomes Expanding access to cancer care Increasing quality and balancing cost Reducing cancer disparities

SWOG’s Contributions to NCORP Clinical Trials & Translational Research Advisory Committee (CTAC) Michael LeBlanc NCI Community Oncology Cardiotoxicity Task Force Carol Fabian Michael Fisch Network Accrual Core Team (ACT) Dana Sparks Karen Anderson Coverage Analysis Working Group Casey Dawson Tameka Lewis

SWOG’s Contributions to NCORP NCI CIRB Adult - Late Phase Emphasis John Ellerton – Nevada Joan Westendorp – West Michigan Adult - Early Phase Emphasis James Bearden – SCOR Cancer Prevention and Control James Wade – Heartland (Chair) David Page - Pacific Connie Szczepanek – West Michigan Loren Tschetter - Sanford Debra Wujcik – Baptist Health

SWOG NCORP Committees Prevention and Epidemiology Cancer Care Delivery Survivorship Symptom Control and Quality of Life

NCORP Study Concepts Submitted (Since NCORP’s Inception) No. of concepts submitted No. of approval % of approved 6 4 66% SWOG has the highest concept approval rate within NCORP

Accruing SWOG NCORP Studies Prevention Committee S0820 (PACES) Cancer Care Delivery Committee S1204 (Viral testing) – Legacy CCD study S1417CD (Financial toxicity) Survivorship Committee S1316 (Prospective comparative effectiveness trial for malignant bowel obstruction) Symptom Control and Quality of Life Committee S1013 (Skin toxicity - treatment effects) – closing 10/1/16 S1200 (Acupuncture – AIs induced joint pain) PRO Translational Medicine endpoints are being added to many therapeutic protocols

SWOG NCORP Studies in Follow-up Prevention Committee S0812 (Vitamin D for high breast cancer risk) Cancer Care Delivery Committee S1105 (Text messaging to help AI medication) – Legacy CCD study Survivorship Committee S1008 (Weight loss intervention by physical activity, diet, and counseling ) Symptom Control and Quality of Life Committee S0702 (Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases - registry) We need your help to complete the data collection and follow-up for these important trials!

SWOG NCORP Studies Opening Soon Cancer Care Delivery Committee S1415CD-TRACER (Prophylactic G-CSF delivery) Survivorship Committee S1501 (Cardiotoxicity)

SWOG’s Top Leadership

SWOG NCORP Committee Leadership Cancer Care Delivery - Dawn Hershman, MD, MS and Scott Ramsey, MD, PhD Cancer Survivorship Carol Fabian, MD and Robert Krouse, MD, FACS Prevention and Epidemiology Marian Neuhouser, PhD, RD and Banu Arun, MD Symptom Control and Quality of Life Michael Fisch, MD, PhD and Lynn Henry, MD

SWOG’s UG1 Grant and Program Involvement

Happy Sixtieth Birthday! SWOG Happy Sixtieth Birthday! Thank you!